Purpose: The aim of the this study was to determine the effect of intravitreal antivascular endothelial growth factor injections on intraocular pressure (IOP) and identify possible risk factors for the development of increased IOP. Materials and Methods: This prospective study included a total of 106 eyes receiving intravitreal injection of bevacizumab as treatment for macular edema or active choroidal neovascularization. IOP was measured by Goldmann applanation tonometry immediately before the intravitreal injection and 5 min, 1 h and 15 days after the procedure. The records of the study patients were reviewed for age, gender, history of glaucoma, diabetes mellitus, phakic status, systemic and topical medication and number of previous injections. Subconjunctival reflux was registered. IOP elevation was defined as IOP ≥21 mm Hg and/or a change from baseline of ≥5 mm Hg recorded at least on two or more measurements on the same visit. Results: Mean preoperative IOP was 15.31 ± 3.90 mm Hg and postoperative IOP values were 27.27 ± 11.87 mm Hg (after 5 min), 17.59 ± 6.24 mm Hg (after 1 h) and 16.86 ± 3.62 mm Hg (after 15 days). The IOP variation was statistically significant between pre- and postoperative measurements (p < 0.05). Subconjunctival reflux was recorded in 11.3%, and in this subgroup the IOP at 5 min and at 1 h was lower than preoperative IOP (p < 0.05). Conclusions: More than one third of the eyes achieved IOPs >30 mm Hg 5 min after injection. Subconjunctival reflux contributed to a lower mean postoperative IOP (p < 0.05). Considerations for the management include prophylactic IOP lowering with medical therapy and/or preinjection ocular decompression for patients with a history of glaucoma or ocular hypertension and switching to an as-needed injection protocol in patients suffering a marked IOP rise in previous injections.

Keywords:
Intraocular pressure, Risk factors, Intravitreal injection, Antivascular endothelial growth factor
1.
Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, Geyer O: Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1435-1440.
2.
CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
3.
Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J: Short term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
4.
Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J: Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptinib, and bevacizumab. Eye (Lond) 2009;23:181-185.
5.
Aref AA: Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol 2012;23:105-110.
6.
Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
7.
Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
8.
Good TJ, Kimura AE, Mandava N, Kahook MY: Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
9.
Gismondi M , Salati C, Salvetat ML, et al: Short-term effect of intravitreal injection of ranibizumab on intraocular pressure. J Glaucoma 2009;18:658-661.
10.
Kim JE, Mantravadi AV, Hur EY, Covert DJ: Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-934.
11.
Falkenstein IA, Cheng L, Freeman WR: Changes of intraocular pressure after intravitreal injection of bevacizumab. Retina 2007;27:1044-1047.
12.
Michelson G, Groh MJ, Langhans M: Perfusion of the juxtapapillary retina and optic nerve head in acute ocular hypertension. Ger J Ophthalmol 1996;5:315-321.
13.
Menke MN, et al: Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab. Ophthalmologica 2013;229:168-172.
14.
Tranos P, Bhar G, Little B: Postoperative intraocular pressure spikes: the need to treat. Eye (Lond) 2004;18:673-679.
15.
Savage JA, Thomas JV, Belcher CD 3rd, Simmons RJ: Extracapsular cataract extraction and posterior chamber intraocular lens implantation in glaucomatous eyes. Ophthalmology 1985;92:1506-1516.
16.
Kolker AE: Visual prognosis in advanced glaucoma: a comparison of medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc 1977;75:539-555.
17.
El Chehab H , Le Corre A, Giraud JM, Ract-Madoux G, Swalduz B, Dot C: Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections (in French). J Fr Ophtalmol 2012;35:614-621.
18.
Saeed MU, Qureshi F, Batra R, Clark D: Effect of reflux drug during intravitreal anti-VEGF therapies on foveal thickness. Semin Ophthalmol 2011;26:61-63.
19.
Lorenz K, Zwiener I, Mirshahi A: Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch Clin Exp Ophthalmol 2010;248:1573-1577.
20.
Özkaya A, Alkin Z, Celik U, Yüksel K, Ozgurhan EB, Ağca A, Yazici AT, Demirok A: Comparing the effects of three different intravitreal injection techniques on vitreous reflux and intraocular pressure. J Ocul Pharmacol Ther 2013;29:325-329.
21.
Rodrigues EB, Grumann A Jr, Penha FM, Shiroma H, Rossi E, Meyer CH, Stefano V, Maia M, Magalhaes O Jr, Farah ME: Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther 2011;27:197-203.
22.
Saeed MU, Batra R, Qureshi F, Clark D: Reflux of drug during intra-vitreal anti-VEGF therapies. Semin Ophthalmol 2011;26:357-360.
23.
Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingermann RO, Weichselberger A, Staurenghi G: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-671.
24.
Abegão Pinto L, Vandewalle E, Willekens K, Marques-Neves C, Stalmans I: Ocular pulse amplitude and Doppler waveform analysis in glaucoma patients. Acta Ophthalmol 2014;92:e280-e285.
25.
Stalmans I, Harris A, Vanbellinghen V, Zeyen T, Siesky B: Ocular pulse amplitude in normal tension and primary open angle glaucoma. J Glaucoma 2008;17:403-407.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.